Low-dose methotrexate in myeloproliferative neoplasm models.
作者信息
Chinnaiya Kavitha, Lawson Michelle A, Thomas Sally, Haider Marie-Therese, Down Jenny, Chantry Andrew D, Hughes David, Green Antony, Sayers Jon R, Snowden John A, Zeidler Martin P
机构信息
The Bateson Centre, Department of Biomedical Science, The University of Sheffield, UK.
Department of Oncology & Metabolism, The University of Sheffield, UK.
出版信息
Haematologica. 2017 Sep;102(9):e336-e339. doi: 10.3324/haematol.2017.165738. Epub 2017 May 26.
Abstract
摘要
相似文献
1
Low-dose methotrexate in myeloproliferative neoplasm models.低剂量甲氨蝶呤在骨髓增殖性肿瘤模型中的应用
Haematologica. 2017 Sep;102(9):e336-e339. doi: 10.3324/haematol.2017.165738. Epub 2017 May 26.
2
Low-dose methotrexate: potential clinical impact on haematological and constitutional symptoms in myeloproliferative neoplasms.低剂量甲氨蝶呤：对骨髓增殖性肿瘤血液学和全身症状的潜在临床影响
Br J Haematol. 2019 Nov;187(3):e69-e72. doi: 10.1111/bjh.16193. Epub 2019 Sep 16.
3
Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.JAK2（V617F）骨髓增殖性肿瘤患者中 PD-L1 的异位表达是通过 STAT3 和 STAT5 的激活增加介导的。
Hum Cell. 2020 Oct;33(4):1099-1111. doi: 10.1007/s13577-020-00370-6. Epub 2020 Jul 14.
4
Metformin exerts multitarget antileukemia activity in JAK2-positive myeloproliferative neoplasms.二甲双胍在 JAK2 阳性骨髓增生性肿瘤中发挥多靶点抗白血病活性。
Cell Death Dis. 2018 Feb 22;9(3):311. doi: 10.1038/s41419-017-0256-4.
5
HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?JAK2+骨髓增殖性肿瘤间充质基质细胞中HDAC8的过表达：一个新的治疗靶点？
Oncotarget. 2017 Apr 25;8(17):28187-28202. doi: 10.18632/oncotarget.15969.
6
Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2 against myeloproliferative neoplasms.发现并评价 ZT55，一种新型针对骨髓增殖性肿瘤的 JAK2 高选择性酪氨酸激酶抑制剂。
J Exp Clin Cancer Res. 2019 Feb 4;38(1):49. doi: 10.1186/s13046-019-1062-x.
7
The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.骨髓增殖性肿瘤中的 JAK2V617F 等位基因负担和 STAT3 及 STAT5 磷酸化：早期前纤维化性骨髓纤维化与原发性血小板增多症、真性红细胞增多症和骨髓纤维化的比较。
APMIS. 2011 Aug;119(8):498-504. doi: 10.1111/j.1600-0463.2011.02754.x. Epub 2011 Apr 17.
8
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.来他替尼（CEP701）是一种JAK2抑制剂，可抑制JAK2/STAT5信号传导以及骨髓增殖性疾病患者原代红细胞的增殖。
Blood. 2008 Jun 15;111(12):5663-71. doi: 10.1182/blood-2007-04-083402. Epub 2007 Nov 5.
9
Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours.Withacnistin 通过抑制 STAT3 和 STAT5 向生长因子和细胞因子受体的募集，诱导乳腺肿瘤消退。
Br J Cancer. 2014 Aug 26;111(5):894-902. doi: 10.1038/bjc.2014.349. Epub 2014 Jul 1.
10
Tetrandrine, an agonist of aryl hydrocarbon receptor, reciprocally modulates the activities of STAT3 and STAT5 to suppress Th17 cell differentiation.粉防己碱，一种芳烃受体激动剂，可相互调节信号转导和转录激活因子3（STAT3）及信号转导和转录激活因子5（STAT5）的活性，以抑制辅助性T细胞17（Th17）细胞分化。
J Cell Mol Med. 2017 Sep;21(9):2172-2183. doi: 10.1111/jcmm.13141. Epub 2017 Mar 22.
引用本文的文献
1
Case report: Effectiveness of low-dose methotrexate monotherapy in post-essential thrombocythemia myelofibrosis.病例报告：低剂量甲氨蝶呤单药治疗原发性血小板增多症后骨髓纤维化的疗效
Front Med (Lausanne). 2024 Apr 18;11:1285772. doi: 10.3389/fmed.2024.1285772. eCollection 2024.
2
Crystal structure of the human PRPK-TPRKB complex.人源 PRPK-TPRKB 复合物的晶体结构。
Commun Biol. 2021 Feb 5;4(1):167. doi: 10.1038/s42003-021-01683-4.
3
Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity.细胞因子诱导的 Jak/STAT 信号转导减弱与类风湿关节炎及疾病活动度相关。
PLoS One. 2021 Jan 14;16(1):e0244187. doi: 10.1371/journal.pone.0244187. eCollection 2021.
4
JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy.甲氨蝶呤（和 csDMARDs）对 JAK 的抑制作用可能解释了其作为单药治疗和联合治疗的临床疗效。
J Leukoc Biol. 2019 Nov;106(5):1063-1068. doi: 10.1002/JLB.5RU0519-145R. Epub 2019 Jul 16.
本文引用的文献
1
Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin.一种泛 Janus 激酶抑制剂临床候选药物（PF-06263276）的设计与合成，适合吸入和局部递送来治疗肺部和皮肤的炎症性疾病。
J Med Chem. 2017 Jan 26;60(2):767-786. doi: 10.1021/acs.jmedchem.6b01634. Epub 2017 Jan 4.
2
Low-dose methotrexate as treatment of myeloproliferative neoplasms: Proof of principle of clinical activity.低剂量甲氨蝶呤治疗骨髓增殖性肿瘤：临床活性的原理验证
Am J Hematol. 2016 Aug;91(8):E329-30. doi: 10.1002/ajh.24406. Epub 2016 Jun 3.
3
Recent advances in understanding myelofibrosis and essential thrombocythemia.骨髓纤维化和原发性血小板增多症认识方面的最新进展。
F1000Res. 2016 Apr 19;5. doi: 10.12688/f1000research.8081.1. eCollection 2016.
4
Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.接受鲁索替尼或标准治疗的真性红细胞增多症患者的生活质量和疾病相关症状的变化。
Eur J Haematol. 2016 Aug;97(2):192-200. doi: 10.1111/ejh.12707. Epub 2016 Jan 3.
5
Methotrexate Is a JAK/STAT Pathway Inhibitor.甲氨蝶呤是一种JAK/STAT信号通路抑制剂。
PLoS One. 2015 Jul 1;10(7):e0130078. doi: 10.1371/journal.pone.0130078. eCollection 2015.
6
Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study.1973 年至 2005 年间瑞典被诊断为骨髓增生性肿瘤患者的风险和死亡原因：一项基于人群的研究。
J Clin Oncol. 2015 Jul 10;33(20):2288-95. doi: 10.1200/JCO.2014.57.6652. Epub 2015 Jun 1.
7
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.芦可替尼与标准疗法治疗真性红细胞增多症的对比
N Engl J Med. 2015 Jan 29;372(5):426-35. doi: 10.1056/NEJMoa1409002.
8
Mechanisms of Jak/STAT signaling in immunity and disease.Jak/STAT信号通路在免疫及疾病中的作用机制
J Immunol. 2015 Jan 1;194(1):21-7. doi: 10.4049/jimmunol.1401867.
9
Transient low-dose methotrexate generates B regulatory cells that mediate antigen-specific tolerance to alglucosidase alfa.短暂低剂量甲氨蝶呤可产生B调节细胞，这些细胞介导对阿糖苷酶α的抗原特异性耐受。
J Immunol. 2014 Oct 15;193(8):3947-58. doi: 10.4049/jimmunol.1303326. Epub 2014 Sep 10.
10
JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease.JAK2V617F 纯合子驱动骨髓增殖性肿瘤的表型转换，但不足以维持疾病。
Blood. 2014 May 15;123(20):3139-51. doi: 10.1182/blood-2013-06-510222. Epub 2014 Apr 1.
Zotero 插件